Table 1.

Multiple myeloma cases in this study

MM no.	Figure no.	Age, y/sex	Ig isotype	Stage*	No. of prior treatments	CD138+, %	Ki67+/CD138+, %
1	6F	59/F	Gκ	III	1	< 5	NA
2	NS	43/F	κ†	II	1	60	< 1
3	6B	46/F	Gκ	II	0	30	2
4	S6A	36/F	Gκ	III	2	60	12
5	6D	57/F	κ†	III	7	90	49
6	S6A	44/F	Gκ	III	1	< 5	< 1
7	6B	55/F	Gκ	III	0	80	42
8	6E	63/M	κ†	III	3	30	16
9	6B	60/M	Gκ	III	2	30	8
10	6F-G	55/F	Gκ	III	2	90	71
13	S6B	72/F	Aκ	III	1	80	22
14	NS	82/F	Gλ	III	0	50	4
15	6B	44/M	λ†	II	0	80	8
16	6A	68/M	λ†	II	1	10	3
17	NS	58/M	Gκ	II	0	30	2
18	S6B	74/M	Gκ	II	0	25	2
20	S6A	71/F	Gκ	III	7	90	2
21	NS	58/M	Gκ	III	6	90	14
22	NS	76/F	Gλ	III	10	95	25
23	NS	85/M	κ†	II	4	80	6
24	NS	60/M	Gκ	III	7	5	NA
25	S6A	76/F	Gκ	III	0	40	12
26	NS	61/F	Gκ	III	8	90	25
27	6B	46/F	λ†	II	8	100	35
28	6C	71/F	Gλ	III	1	NA	NA

Ig indicates immunoglobulin; NS, data not shown in those MM cases in which PD 0332991 does not significantly enhance bortezomib killing of MM cells in vitro; NA, data not available; S6A, supplemental Figure 6A; and S6B, supplemental Figure 6B.

^*Durie-Salmon staging.³⁹ Double immunohistochemical staining of CD138 and Ki67 was performed on core bone marrow biopsies as previously described. % CD138⁺ means the percentage of BM cells that are CD138 positive and % Ki67/CD138⁺ means the percentage of Ki67 positive cells among the CD138 positive cells.¹⁹

^†Absence of Ig heavy chains.